Abstract
Introduction
Crohn's disease [CD] often has important negative effects on patients' health-related quality of life [HRQOL] , because of the impacts of disease on both physical and mental well-being. HRQOL is usually assessed by either the 36-item Short-Form Health Survey [SF-36], a generic multi-item scale that evaluates both physical [PCS] and mental component summary scores [MCS] , 1 or a disease-specific instrument: the Inflammatory Bowel Disease Questionnaire [IBDQ] . 2 Previous studies have shown that SF-36 is a reliable and valid instrument to measure general health status in patients with CD. 3 Importantly, as can only be determined using a generic instrument, patients with CD have substantially impaired HRQOL compared with the general population. 4 Furthermore, the effects of the disease on SF-36 MCS scores is relatively more profound than observed in other chronic inflammatory diseases such as rheumatoid arthritis.
The IBDQ, a 32-item questionnaire comprising four domains [bowel symptoms, systemic symptoms, emotional function, and social function] is the most commonly used disease-specific measure for evaluation of HRQOL in CD. The IBDQ is more sensitive than the SF-36 to clinically meaningful changes in health status, and therefore can be used to detect relatively small differences in treatment effects in specific disease subgroups or drug treatment regimens.
Ustekinumab, a monoclonal antibody to the p40 subunit of interleukins [IL]-12 and -23, is approved for the treatment of active CD based on the results of three Phase 3 studies. 5 Herein we report the effects of ustekinumab on HRQOL in patients with moderate to severe CD.
Methods
The UNITI and IM-UNITI studies were multicentre, randomised, double-blind, placebo-controlled Phase 3 studies designed to evaluate the safety and efficacy of ustekinumab induction and maintenance therapy in patients with moderately to severely active CD.
Briefly, patients with moderately to severely active CD (defined by a CD Activity Index [CDAI] score of 220-450) and with inadequate response or intolerance to tumour necrosis factor [TNF] antagonists in SF-36 PCS and MCS scores. 8, 9 Patients with an IBDQ score ≥170 points were considered to be in clinical remission. 10 Additionally, IBDQ normalisation defined as a score ≥210 points, 7 and SF-36 PCS or MCS normalisation defined as scores ≥50 points 11 among patients with abnormal baseline values, were also evaluated in post hoc analyses.
Statistical analysis
The Type 1 error rate within each study was controlled at 0.05 for the primary and major secondary endpoints, using a hierarchical testing procedure. The HRQOL outcomes described herein were pre-specified; however, statistical contrasts were not adjusted for multiplicity. The following missing data conventions were used for these analyses. Each of the four individual IBDQ dimensions was calculated when ≤1 item was missing in the dimension. The missing item was estimated using the average value across the non-missing items. If any one of the dimensions within the IBDQ could not be calculated, then the total IBDQ score was not be calculated.
For SF-36 scores, subscales were calculated whenever ≥50% of the items that comprised the individual subscale were available [non-missing]. Any missing items were estimated using the average value across the non-missing items for that subscale. If <50% of the items that comprised the subscale were available, the subscale was not calculated. If any of the individual subscales that comprised the PCS or MCS score was missing, then these scores could not be calculated. Figure 1A , B]. A numerically greater treatment effect relative to placebo was seen in UNITI-2 than UNITI-1 [ustekinumab 130 mg, 14.4 versus 6.2; ustekinumab 6 mg/kg, 20.6 versus 10.2, respectively]. For both studies, changes in the mean IBDQ scores at Week 8 were significantly greater in both ustekinumab dose groups compared with placebo and across all dimensions [p <0.05 for all comparisons]. In both studies, changes in the mean IBDQ dimension scores at Week 8 were significantly greater in the ustekinumab 6 mg/ kg group compared with placebo and across all dimensions [p <0.001 for all comparisons]. In the ustekinumab 130 mg group, mean changes at Week 8 were significantly greater for the social and systemic dimensions [p <0.05 for both comparisons], and numerically greater for the bowel and emotional dimensions compared with placebo in UNITI-1 [ Figure 2A , B]. In UNITI-2, this comparison was only statistically significant for the comparison of ustekinumab 6 mg/kg with placebo [5.8% versus 1.4%, p = 0.019].
SF-36 results
In both studies, the mean baseline SF-36, PCS, and MCS scores were similar among the three treatment groups [ Table 1 ; Figure 1C -F]. In UNITI-1 at Week 8, the mean change from baseline in the PCS score was numerically, but not significantly, greater in the both ustekinumab dose groups compared with the placebo group. The mean change from baseline in the MCS score at that time was significantly greater in the ustekinumab 6 mg/kg group [p = 0.006], but only numerically greater for the ustekinumab 130 mg group compared with the placebo group. In UNITI-2, the mean changes from baseline in the MCS and PCS scores were significantly greater for both ustekinumab groups compared with the placebo group [p <0.05 for all comparisons; Table 1 ].
In UNITI-1, mean changes from baseline in norm-based scores of the SF-36 scales at Week 8 were numerically greater in both ustekinumab groups compared with placebo; however, the ustekinumab 6 mg/kg group showed relatively greater differences, with statistically significant differences observed for bodily pain, vitality, social functioning, and mental health scales [ Table 2 ]. In UNITI-2, the mean changes from baseline in norm-based scores of the SF-36 scales at Week 8 were significantly greater in both ustekinumab groups compared with the placebo group [p <0.05 for all comparisons; Table 2 ].
In UNITI-2, the proportion of patients with a clinically meaningful improvement in PCS was significantly greater for the ustekinumab 6 mg/kg and 130 mg groups than for the placebo group [49.2% and 44.0%, respectively versus 31.2%; p <0.001 and p = 0.009, respectively]. More patients experienced clinically significant improvement in MCS in both the ustekinumab 6 mg/kg and 130 mg groups than the placebo group [51.3% and 49.2%, respectively, versus 38.6%; p = 0.014 and p = 0.036, respectively]. In UNITI-1, MCS scores were only significantly greater for the ustekinumab 6 mg/kg group in comparison with the placebo group [42.4% versus 30.0%; p = 0.007] [ Figure 2A , B].
For patients with impaired SF-36 scores at baseline, defined as less than the US population norm of 50 points, greater proportions of patients receiving either ustekinumab dose had normal MCS and PCS scores compared with placebo at Week 8 [ Figure 2A , B]. These differences were statistically significant in UNITI-2 for the MCS [with both ustekinumab doses] and for the PCS in the ustekinumab 6 mg/kg group.
Maintenance study

IBDQ results
At baseline of the maintenance study [ Figure 3A ]. At Week 20, the mean decrease [worsening] in IBDQ score from maintenance baseline was significantly less in the ustekinumab 90 mg q12w group and numerically less in the ustekinumab q8w dose group compared with the placebo group [p = 0.035 and p = 0.183, respectively; Table 3 ]. At Week 44, the mean decreases in IBDQ scores from maintenance baseline were significantly less in the ustekinumab q12w and q8w dose groups (-8 Figure 3A ]. These results indicate that patients who received ustekinumab were more likely to maintain the improvement in their IBDQ scores achieved during induction compared with patients who discontinued ustekinumab treatment.
The proportion of patients with a clinically meaningful improvement in IBDQ score at Week 44 was significantly greater than placebo for the ustekinumab q8w dose but not for the ustekinumab q12w a Patients who were in clinical response to ustekinumab IV induction dosing and were randomised to placebo SC on entry into this maintenance study. Patients who had a prohibited Crohn's disease-related surgery, had a loss of response, had prohibited concomitant medication changes, or discontinued study agent due to lack of efficacy or due to an adverse event indicated to be worsened Crohn's disease before the designated analysis timepoint had their induction baseline value carried forward. dose group [67.9% and 61.3%, respectively, versus placebo 50.4%; p = 0.014 and p = 0.140, respectively; Figure 4 ]. Among patients with IBDQ scores of <210 points at baseline of an induction study, greater proportions of patients receiving either ustekinumab dose, than placebo, achieved normal scores at Week 44 following maintenance treatment [ Figure 4 ].
SF-36 results
The mean PCS and MCS scores of the SF-36 at baseline of maintenance [induction Week 8] were similar among the three treatment groups [ Table 4 ; Figure Patients who were in clinical response to ustekinumab IV induction dosing and were randomised to placebo SC on entry into this maintenance study.
b
Patients who had a prohibited Crohn's disease-related surgery, had a loss of response, had prohibited concomitant medication changes, or discontinued study agent due to lack of efficacy or due to an adverse event indicated to be worsened Crohn's disease before the designated analysis timepoint had their induction baseline value carried forward. c Patients who had insufficient data at the designated analysis timepoint had their last value carried forward. *p <0.050; **p <0.010; ***p <0.001. compared with the placebo group [ Table 4 ]. For the ustekinumab q12w group, only the mean decrease from baseline during maintenance in the MCS score at Week 44 was significantly less compared with the placebo group. For the SF-36 PCS and MCS scores, both the ustekinumab q8w and q12w dose groups had significantly greater proportions of patients with a clinically meaningful [≥5-point] improvement, except for the PCS in the ustekinumab q12w group [ Figure 4 ]. A significantly greater proportion of patients in the ustekinumab q8w group achieved clinically-meaningful improvement in PCS than in the placebo group [52.1% versus placebo, 34.7%; p = 0.008], and a significantly greater proportion of patients in the ustekinumab q8w and q12w dose groups achieved a clinically meaningful improvement in MCS than the placebo group at Week 44 [47.9% and 46.7%, respectively, versus placebo, 28.9%; p = 0.003 and p = 0.005, respectively; Figure 4 ].
For patients with baseline SF-36 scores lower than the US population norm, greater proportions of patients in both ustekinumab dose groups had normal MCS and PCS scores at Week 44 [ Figure 4 ]. These results were significantly greater with ustekinumab q8w for both MCS and PCS.
The mean SF-36 dimension scores [i.e. physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health] were generally consistent across all groups at baseline of the maintenance study. At Week 44, the mean worsening from baseline in the SF-36 dimension scores was generally less in the ustekinumab q12w and q8w groups compared with the placebo group [ Table 5 ]. Specifically, the mean decreases [worsening] in general health, vitality, and mental health dimension scores in the ustekinumab q12w group were significantly less than those observed in the placebo group at Week 44, whereas the mean worsening in six of the eight dimension scores [physical functioning, role-physical, bodily pain, vitality, social functioning, and mental health] in the ustekinumab q8w group were significantly less than those observed for the placebo group at Week 44.
Discussion
At study entry, participants in the UNITI trials had active CD with IBDQ and SF-36 scores consistent with moderate to severe impairment of HRQOL. 10 Following treatment with IV ustekinumab 6 mg/ kg or 130 mg, HRQOL scores improved considerably relative to placebo.
At Week 8, greater proportions of patients receiving either ustekinumab 6 mg/kg or 130 mg demonstrated clinically important improvement in total IBDQ scores compared with placebo, with a greater effect evident in those who received the regulatory approved 6 mg/kg dose. Consistent with these observations, greater a Patients who were in clinical response to ustekinumab IV induction dosing and were randomised to placebo SC on entry into this maintenance study.
Patients who had a prohibited Crohn's disease-related surgery, had a loss of response, had prohibited concomitant medication changes, or discontinued study agent due to lack of efficacy or due to an adverse event indicated to be worsened Crohn's disease before the designated analysis timepoint had their induction baseline value carried forward. Patients who had insufficient data at the designated analysis timepoint had their last value carried forward. *p <0.050; **p <0.010; ***p <0.001. proportions of patients receiving ustekinumab 6 mg/kg and 130 mg demonstrated clinically significant improvement compared with placebo in both the PCS and MCS scores. Likewise, greater proportions of patients in the ustekinumab 6 mg/kg group achieved normal IBDQ, PCS, and MCS scores. It is noteworthy that HRQOL normalisation was more pronounced among ustekinumab-treated patients with an inadequate response or intolerance to conventional CD therapy [UNITI-2 population] than to TNF antagonists [UNITI-1 population]. This phenomenon, which was also observed in a recent analysis of patients treated with vedolizumab, is likely due to the greater prevalence of structural bowel damage in UNITI-1 participants who had higher disease activity and longer disease duration than those evaluated in UNITI-2.
At the baseline visit of IM-UNITI, the mean baseline IBDQ scores approached the criterion for remission [≥170 points] and both PCS and MCS scores approximated the general US population mean norms of 50. At Week 44 in IM-UNITI, a dose-response relationship was observed with patient-reported outcomes, as was previously reported for improvements in signs and symptoms. 5 This dose-response relationship favoured patients receiving q8w maintenance dosing compared with q12w dosing. Mean reductions in IBDQ scores from baseline at entry to IM-UNITI [i.e. Week 8] for the ustekinumab q12w and q8w dose groups were both significantly less compared with those assigned to placebo. This was also observed with SF-36 scores, where ustekinumab q8w was more likely to maintain improvement from induction therapy than ustekinumab q12w as measured by both the MCS and the PCS scores.
This dose-response between q8w and q12w dosing at Week 44 was more apparent in parameters evaluating the more stringent endpoints of patients achieving clinically-important improvement in IBDQ, PCS, or MCS, or normalisation of IBDQ, PCS, or MCS scores. These results are consistent with the Week 44 primary endpoint [clinical remission] and major secondary endpoints [clinical response, remission in remitters, corticosteroid-free remission, and remission in TNF-naïve patients] where the ustekinumab q8w group was numerically greater than the q12w group for all endpoints. 5 Collectively, these findings support the choice of the q8w dose regimen as being optimal for maintaining improved quality of life in patients who responded to induction therapy with ustekinumab.
Previous studies with TNF antagonists, including infliximab, natalizumab, adalimumab, and vedolizumab, have shown that maintenance treatment with these therapies results in improved HRQOL in patients as assessed by multiple patient-reported outcome instruments. [12] [13] [14] [15] In conclusion, ustekinumab improved general health status and inflammatory bowel disease-specific HRQOL after a single intravenous infusion in patients with moderately to severely active CD, particularly ustekinumab 6 mg/kg, and improvements were better maintained with subcutaneous ustekinumab 90 mg q8w or q12w as compared with placebo. These results mirror the efficacy in clinical outcomes and inflammatory biomarkers reported previously. 
